Ilofotase alfa

About AM-Pharma

AM-Pharma is a clinical-stage biotech developing ilofotase alfa, a recombinant alkaline phosphatase therapy for adult hypophosphatasia (HPP). The drug has demonstrated promising effects on disease biomarkers and a favorable safety profile in a Phase 1b proof-of-concept study, positioning it as a potential treatment for an underserved adult patient population. The company is privately held, pre-revenue, and is advancing its lead program based on a targeted enzyme replacement platform.

Therapeutic Areas